28.07.2011 • NewsGenzymePharmaQ2 2011

Sanofi-Aventis Q2 Profit Slips

Sanofi-Aventis reported a 13.2% decline in its second-quarter business net income to €2.15 billion  from €2.48 billion last year. Business earnings per share were €1.64, down 13.7% from €1.90 in the 2010 second quarter. At constant exchange rates, business earnings per share decreased by 7.4%.

Net income attributable to equity holders of Sanofi for the same period dropped 41.1% to €1.0 billion from €1.71 billion a year earlier. Consolidated earnings per share were € 0.77, lower than €1.31 in the previous year.
Net sales in the second quarter of 2011 totaled €8.35 billion compared with €8.31 billion in the same period a year ago. Total sales at constant exchange rates grew 6.9%, thanks to the Genzyme acquisition and performance of growth platforms, the company said.

In addition, the company said it expects 2011 business earnings per share to be 2% to 5% lower than 2010 business EPS7 at CER, barring major unforeseen adverse events. This guidance does not assume a return of generics of Eloxatin in the U.S.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.